Results 231 to 240 of about 10,186,856 (344)

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Exploring relationships between college students' social networks, social support, and mental health during the COVID-19 pandemic. [PDF]

PLOS Ment Health
Broda MD, Wang TW, Hui J, Ross E, McGinnis HA, Chan DM, Tomlinson CA, Luce C.   +7 more
europepmc   +1 more source

Dataset Supporting the Article of the Determinants of Urban Shrinkage in small-sized Cities: A Path Analysis of Demographic Decline in Harsin, Iran

Gholami Gowhareh, Mohammadreza
openalex   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Inhibition of Particle Growth During Single-Pulse Laser Fragmentation by Barrierless Adsorption of the Just-Formed Gold Nanoparticles on Graphene Oxide. [PDF]

Chemphyschem
Tack M, Plech A, Pokhrel Y, Dolling M, Ahrens M, Hüttmann G, Reichenberger S.   +6 more
europepmc   +1 more source

Sizing SiC storage inverters for fast grid frequency support

, 2015
Andy Hoke, Kevin Bennion, Vahan Gevorgian, Sudipta Chakraborty, Eduard Muljadi   +4 more
openalex   +2 more sources

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Synergistic enhancement of hydrogen evolution reaction <i>via</i> N and Ni co-doping in TiO₂-modified Pt/C catalysts. [PDF]

RSC Adv
Lin X, Wei H, Zhang Y, Chi H, Liu X, Xi Y.   +5 more
europepmc   +1 more source

(Main Measures to Support the Development of Small and Medium-Sized Enterprises in the World)

, 2017
Вера Баринова, Степан Земцов, T. Lanshina   +2 more
openalex   +1 more source